Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol

2025/07/07 by L.R. Murphy, Nicholas D James, Nicholas D. James +4242 · 1 voice · 2 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Cancer Risks and Factors #Cancer, Lipids, and Metabolism #Metabolism, Diabetes, and Cancer

paper · pdf · doi:10.1016/s1470-2045(25)00231-1

openalex publication_date 2025/07/07 · openalex created_date 2025/07/07 · crossref created 2025/07/07 · crossref issued 2025/08/01 · crossref published 2025/08/01 · crossref published-print 2025/08/01 · crossref deposited 2025/10/01 · crossref indexed 2026/07/11 · openalex updated_date 2026/07/31

Citations

• Hallmarks of Cancer: New Dimensions
• EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer
• Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them

Cited by

• Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer
• The anti-obesogenic metabolite, Lac-Phe, is elevated by metformin treatment in prostate cancer patients

Discussions

• Could adding metformin to standard treatment help reduce side effects in men with advanced #ProstateCancer? A team led by Prof Noel Clarke @manchester.ac.uk share exciting new findings in @thelanceto [bsky, 1 points, 1 comments]